VICTORION-Difference: Inclisiran-Based Strategy vs. Standard of Care
Current clinical challenges in lipid control include achieving and maintaining target LDL-cholesterol levels in patients at high risk for atherosclerotic cardiovascular disease, especially those who do not respond adequately to standard therapies. The VICTORION-Difference trial demonstrated that an inclisiran-based treatment strategy significantly outperformed usual care in helping patients reach early and sustained LDL-C goals. This approach also resulted in fewer muscle-related side effects, a common barrier to adherence. Inclisiran offers a convenient, effective, and well-tolerated option for improving lipid management in these patients.  In this interview, Drs. Kim A. Williams and Ulf Landmesser discuss "VICTORION-Difference: Inclisiran-Based Strategy vs. Standard of Care."  Subscribe to ACCELÂ
-------- Â
12:50
--------
12:50
Aortopathies: What A Cardiologist Needs to Know
What if your genes could predict a life-threatening condition before symptoms ever appear? Explore how medical science uncovered the genetic roots of thoracic aortic aneurysm—and why that discovery changed everything. From famous historical figures to modern patients, the implications are profound: understanding the exact genetic mutation can guide treatment and safeguard entire families.  In this interview, Drs. Jeroen J. Bax and John A. Elefteriades discuss "Aortopathies: What A Cardiologist Needs to Know".  Subscribe to ACCELÂ
-------- Â
17:36
--------
17:36
PhysioSync-HF: Conduction System vs. Biventricular Pacing in Cardiac Resynchronization in HFrEF
DAPT-SHOCK-AMI Trial: Cangrelor in Cardiogenic Shock
The DAPT SHOCK AMI trial is the first major study to evaluate antiplatelet therapy specifically in patients with cardiogenic shock (CS) following acute myocardial infarction (AMI). It compares initial treatment strategies using cangrelor versus crushed ticagrelor. Early and potent platelet inhibition is critical for restoring microvascular reperfusion in this high-risk population. Previous randomized trials have excluded these patients, leaving a gap in evidence for optimal antiplatelet management in AMI-CS.  In this interview, Drs. Dipti Itchhaporia and Zuzana Motovska discuss "DAPT-SHOCK-AMI Trial: Cangrelor in Cardiogenic Shock". Subscribe to ACCELÂ
-------- Â
10:57
--------
10:57
ODYSSEY-HCM: Mavacamten in nHCM
The ODYSSEY-HCM trial found that mavacamten did not significantly improve exercise capacity or patient-reported outcomes in individuals with symptomatic nonobstructive hypertrophic cardiomyopathy. Safety concerns emerged, including more frequent reductions in ejection fraction and treatment interruptions among those receiving mavacamten. The trial's limited diversity and short duration raise questions about the generalizability and long-term implications of the findings. Despite the lack of approved therapies for this patient group, the study underscores the complexity of using surrogate endpoints and the need for deeper exploration into disease mechanisms and treatment response.  In this interview, Matthew Martinez MD, FACC and Milind Y. Desai, MD, MBA, FACC discuss "ODYSSEY-HCM: Mavacamten in nHCM."  Subscribe on Apple Podcasts | Subscribe to ACCELÂ
About ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
The American College of Cardiology offers select interviews and summaries of cardiology's most interesting research areas from ACCEL's renowned library, hosted by ACCEL Editor-in-Chief Alison L. Bailey, MD, FACC, FAACPVR.
Listen to ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research, anything goes with emma chamberlain and many other podcasts from around the world with the radio.net app
South Africa